BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

BridgeBio Pharma (BBIO) reported Q3 2026 revenue of $353.17M, up 192.6% YoY, and EPS of -$0.42, compared to -$0.95 a year ago. Revenue beat estimates by 19.08%, and EPS surpassed expectations by 30%. Net product revenue was $253.35M, royalty revenue $20.51M, and license/services revenue $79.31M, all compared to analyst estimates. BBIO shares rose 7.6% over the past month, outperforming the S&P 500.

Original reporting
Published Oct 29, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates — source image
Decision brief

The 30-second read

$BBIOBullishHigh
01

Why it matters

The earnings surprise may attract short‑term buying, but long‑term performance depends on pipeline milestones.

02

Market read

The earnings beat provides a fresh catalyst for BBIO, offering a short‑term trading opportunity.

03

What to watch

Future guidance was not disclosed; pipeline risk and cash burn could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

BridgeBio Pharma is a clinical‑stage biotech focused on rare diseases. The Q3 report shows rapid revenue growth from licensing and services.

Company-level read

Ticker impact

$BBIOBullishHigh confidence
Context

BridgeBio Pharma reported Q3 revenue of $353.17M and EPS of -$0.42, both beating consensus estimates.

Expected impact

potential upside as market prices in the revenue and EPS beat

Evidence & confidence

The surprise revenue (+19.08%) and EPS (+30%) exceed expectations, likely prompting buying interest.

Market effects

Biotech sector may see modest lift as a small-cap beat highlights demand for pipeline assets.

US biotech investors could re‑price other small‑cap earnings expectations.

Limited to US biotech niche; no broad market effect.

Counterpoint

Despite the beat, the company remains loss‑making; investors may stay cautious on valuation.

Key entities

  • BridgeBio Pharma

    US‑listed biotech (NASDAQ: BBIO) reporting Q3 2026 results.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.